| Autor: |
Fontanillas P; 23andMe Inc., 223N Mathilda Ave, Sunnyvale, CA, 94086, USA. pfontanillas@23andme.com., Alipanahi B; 23andMe Inc., 223N Mathilda Ave, Sunnyvale, CA, 94086, USA., Furlotte NA; 23andMe Inc., 223N Mathilda Ave, Sunnyvale, CA, 94086, USA., Johnson M; 23andMe Inc., 223N Mathilda Ave, Sunnyvale, CA, 94086, USA., Wilson CH; 23andMe Inc., 223N Mathilda Ave, Sunnyvale, CA, 94086, USA., Pitts SJ; 23andMe Inc., 223N Mathilda Ave, Sunnyvale, CA, 94086, USA., Gentleman R; 23andMe Inc., 223N Mathilda Ave, Sunnyvale, CA, 94086, USA., Auton A; 23andMe Inc., 223N Mathilda Ave, Sunnyvale, CA, 94086, USA. |
| Abstrakt: |
We trained and validated risk prediction models for the three major types of skin cancer- basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma-on a cross-sectional and longitudinal dataset of 210,000 consented research participants who responded to an online survey covering personal and family history of skin cancer, skin susceptibility, and UV exposure. We developed a primary disease risk score (DRS) that combined all 32 identified genetic and non-genetic risk factors. Top percentile DRS was associated with an up to 13-fold increase (odds ratio per standard deviation increase >2.5) in the risk of developing skin cancer relative to the middle DRS percentile. To derive lifetime risk trajectories for the three skin cancers, we developed a second and age independent disease score, called DRSA. Using incident cases, we demonstrated that DRSA could be used in early detection programs for identifying high risk asymptotic individuals, and predicting when they are likely to develop skin cancer. High DRSA scores were not only associated with earlier disease diagnosis (by up to 14 years), but also with more severe and recurrent forms of skin cancer. |
